Soluble CD26 is significantly increased and contributes to the pathophysiology in immune-mediated disease, such as diabetic cardiovascular disease, autoimmune diabetes, inflammatory bowel disease, GVHD, coronavirus-related immunological response, multiple sclerosis (MS), and tumor immune response. This evidence concerns the gene DPP4 and multiple sclerosis.